drugset
drugset / Trial / NCT04374032

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

NCT04374032 ↗

Phase 2/3 Completed 120 enrolled Bosnalijek D.D
RandomizedParallel-groupOpen-labelTreatment

Summary

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection

Timeline

Start
2020-05-01
Primary completion
2020-10-07
Completion
2020-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject metenkefalin Peptide 5 mg —
Subject tridecactide Peptide 1 mg —

Indications

COVID-19